source
- US patients skip half of new high-cost drugs as prices surge past $250KA new report from the Institute for Clinical and Economic Review and West Health finds that only about one-third of patients prescribed newly launched medicines actually fill them within 30 days, w…
- Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rulesDisc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to t…